Article: Servier Laboratories aiming high in China's innovative drug market - Servier China GM.

Article: ABPI "admonishes" Servier and Shire.(Shire and Servier ...
Pharma Marketletter;  March 26, 2007 ;     700+ words ... ... Association of the British Pharmaceutical Industry's Code of Practice was breached by UK drugmaker Shire and Servier Laboratories, the local subsidiary of France's Servier Research Group, according to a statement by the Prescription Medicines ...

Article: Microdosing deal.(Servier Laboratories Ltd. and ...
Chemistry and Industry;  December 19, 2005 ;     663 words ...French pharmaceutical company Servier and the bioanalytical research organisation Xceleron have signed a 12-month rolling collaborative agreement to accelerate drug development using microdosing. Xceleron will provide accelerator mass spectrometry services to assist in taking drugs to market much

Article: Sevier sues Krka over perindopril.(Servier ...
Pharma Marketletter;  July 31, 2006 ;     700+ words ...French drugmaker Laboratories Servier has launched a legal action against the Slovenian generics producer Krka, claiming that the latter has violated its patent through the processes used to make perindopril, a treatment for high blood pressure. Last month, according to Krka, Servier took out a

Article: Servier's agomelatine approved in Europe.(Servier ...
Pharma Marketletter;  March 2, 2009 ;     626 words ...The European Commission has approved Servier's Valdoxan/Thymanax (agomelatine), the first melatonergic antidepressant for the treatment of adult patients with major depressive episodes. One 25mg tablet of the drug taken at bedtime offers new hope for the 33 million people in Europe suffering from

Article: Servier generics unit "not for sale".(Servier ...
Pharma Marketletter;  May 21, 2007 ;     578 words ...France's largest independent drugmaker, Laboratoire Servier's generics subsidiary Biogaran is not for sale, the company's chairman Jacques Servier has said in Paris. "Our plan is to continue," Dr Servier added. His statement is understood to be in response to recent speculation about recent

Article: "Novel Circumstances" Found In Pharmaceutical Patent ...
Mondaq Business Briefing;  July 26, 2007 ;     700+ words ...The recent case of Servier v Apotex generated what the Judge referred to as "novel circumstances" which resulted in a speedy consideration by the Court of Appeal of the court's refusal to maintain an interim injunction against Apotex whilst Servier appealed the order of the High Court to revoke its

Article: Novartis and Servier enter licensing deal for ...
Pharma Marketletter;  April 3, 2006 ;     700+ words ...Swiss drug major Novartis and French pharmaceutical firm Servier have signed a licensing agreement for agomelatine, a Phase III investigational drug for the treatment of major depressive disorder, a condition estimated to affect one in 10 adults in the USA alone. According to Novartis, the novel